D.C. Circuit: FDA Erred In Denying Drug Application Without Holding Hearing
WASHINGTON, D.C. — The U.S. Food and Drug Administration erred in refusing to hold a hearing before denying Vanda Pharmaceuticals Inc.’s application for approval to market the drug tasimelteon as a...To view the full article, register now.
Already a subscriber? Click here to view full article